MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

Clinical trial NCT05194163 · UNKNOWN

Trial details

NCT number: NCT05194163
Sponsor: Neurokine Therapeutics
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Alzheimer Disease

Start date: 2022-05-01
Primary completion: 2024-08-31
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.